- The MRN complex—composed of MRE11, RAD50 and NBS1—is one of the most essential guardians of genome integrity. It acts as the primary sensor of DNA double‑strand breaks (DSBs), the most dangerous form of DNA damage, and coordinates the early steps of the DNA‑damage response. By detecting broken DNA ends, activating ATM signalling and initiating repair through homologous recombination or non‑homologous end joining, the MRN complex ensures that cells maintain genomic stability and avoid catastrophic chromosomal rearrangements.
- MRE11 provides the nuclease activity required for DNA end processing, functioning as both an exonuclease and an endonuclease. RAD50 contributes ATPase activity and long coiled‑coil arms that tether DNA ends, stabilising broken chromosomes and preventing their dissociation. NBS1 acts as a regulatory adaptor that recruits signalling proteins, most notably ATM, enabling rapid activation of the DNA‑damage response. Together, these three proteins form a dynamic scaffold that binds DNA ends, coordinates repair pathway choice and ensures that damaged chromosomes remain structurally intact during repair.
- The MRN complex is among the earliest responders to DNA double‑strand breaks. RAD50’s coiled‑coil arms and zinc‑hook domain allow the complex to bridge DNA ends, while MRE11 binds and processes the termini. NBS1 recruits ATM to the site of damage, enabling ATM autophosphorylation and full activation. Activated ATM phosphorylates numerous substrates, including H2AX, CHK2, BRCA1 and p53, triggering cell‑cycle arrest, chromatin remodelling and repair. If damage is irreparable, ATM signalling promotes apoptosis or other forms of programmed cell death to prevent propagation of genomic instability.
- A central function of the MRN complex is its role in homologous recombination. MRE11 collaborates with CtIP to initiate DNA end resection, generating short 3′ single‑stranded DNA overhangs. These overhangs are extended by EXO1 and DNA2, coated by RPA and later replaced by RAD51, enabling strand invasion and template‑guided repair. Through this mechanism, MRN ensures high‑fidelity repair during S and G2 phases of the cell cycle, when sister chromatids are available as templates.
- Although MRN primarily promotes homologous recombination, it also contributes to non‑homologous end joining. RAD50’s tethering function stabilises DNA ends, while MRE11’s nuclease activity trims incompatible termini. MRN interacts with Ku70/Ku80 and DNA‑PKcs, facilitating ligation by DNA ligase IV. This dual functionality allows MRN to adapt repair strategy depending on cell‑cycle stage, chromatin context and the nature of the DNA break.
- Beyond double‑strand break repair, the MRN complex stabilises stalled replication forks, preventing their collapse into lethal breaks. It also participates in telomere maintenance by regulating TRF2 and preventing chromosome end‑to‑end fusions. These functions link MRN to broader genome‑maintenance networks, including the proteostasis network and the oxidative stress response, which influence DNA repair capacity and cellular stress tolerance.
- Mutations in MRN components cause severe genomic‑instability syndromes. NBS1 mutations lead to Nijmegen breakage syndrome, characterised by microcephaly, immunodeficiency and cancer predisposition. MRE11 mutations cause ataxia‑telangiectasia‑like disorder, which resembles ATM deficiency. MRN dysfunction also contributes to cancer development by promoting chromosomal instability and therapy resistance. Because MRN is essential for double‑strand break repair, tumours with defective MRN components show hypersensitivity to radiotherapy, PARP inhibitors and DNA‑damaging chemotherapeutics.
- In summary, the MRN complex is a master regulator of DNA double‑strand break repair, genome stability and DNA‑damage signalling. Through coordinated action of MRE11, RAD50 and NBS1, MRN senses DNA breaks, activates ATM, initiates homologous recombination and stabilises damaged chromosomes. Its central role in genome maintenance makes MRN a cornerstone of molecular biology and a key therapeutic target in cancer and genomic‑instability disorders.
